MGMT and glioblastoma: In the CheckMate 548 trial, the addition of nivolumab to radiotherapy and temozolomide did not improve OS (mOS 28.9 vs. 32.1 months in nivolumab vs. placebo group, respectively, HR 1.10) or PFS (10.6 months vs. 10.3 months, HR 1.1) in newly diagnosed GBM patients with methylated/indeterminate MGMT promotor [4].